glp-1 medicaid More states consider dropping weight loss drugs from • Stateline Innovative Payment Models, Holistic Medicaid

Subcutaneous injection over the buttock area

In the future, it is necessary to develop more effective reversal therapies, optimize early diagnostic methods, and advance personalized treatment strategies to improve patient outcomes and quality of life

However, drug release kinetics and therapeutic results vary because not all drugs can be encapsulated successfully

The New England Journal of Medicine commentary accompanying SURPASS-2 stated: "The dual incretin approach appears to exploit receptor crosstalk in ways that amplify downstream insulin secretion beyond what GLP-1 receptor agonism alone can achieve at comparable tolerability." [30] SURPASS-1: Monotherapy Benchmark SURPASS-1 (N=478) established monotherapy efficacy, with tirzepatide 15 mg reducing A1C by 2.07 percentage points and body weight by 9.5 kg at 40 weeks versus placebo [31]